JBIO · CIK 0001798749
What Jade Biosciences, Inc. told the SEC could break it.
Jade is a clinical-stage biotech with no product revenue and a $127.4 million net loss in 2025, expecting significant losses for years and planning to fund operations principally through equity offerings — leaving it dependent on continued capital-market access. It owns no manufacturing facilities, outsourcing all preclinical and clinical drug supply, manufacturing, storage, distribution and testing to third-party CMOs, so it relies entirely on those manufacturers' performance and capacity. That outsourced, partly overseas supply chain is also exposed to U.S. pharmaceutical tariffs — including duties on imports from China and South Korea (where it has collaborators) and a September 2025 plan for 100% tariffs on branded or patented pharmaceuticals — which could raise the cost of APIs and bulk drug product for its trials.
3 self-disclosed vulnerabilities, pulled from its own filings, each in the company’s words, with the source. This is the risk register almost nobody reads.
In its own words
What could break it.
Liquidity & debt
- pre-revenue, $127.4M net loss, equity-financing dependencemedium
Jade is a clinical-stage biotech with no product revenue and a $127.4M net loss for 2025; it expects continued significant losses for years and to finance operations principally through equity offerings, making it dependent on capital-market access.
“The Company has not generated any revenue from product sales or other sources and has incurred significant operating losses and negative cash flows from operations since inception. The Company has incurred a net loss of $ 127.4 million for the year ended December 31, 2025”
SEC filing →As of 2026
Regulatory & policy
- pharma import tariffs (100% branded/patented; China/Korea)medium
Jade faces US tariff exposure — tariffs on imports from China and South Korea, and a September 2025 plan for 100% tariffs on imported branded/patented pharmaceuticals — which could raise the cost of APIs and bulk drug products used in its clinical trials (it has China-based collaborators).
“In September 2025, President Trump announced plans to impose 100% tariffs on imported branded or patented pharmaceuticals, unless the importing company is building U.S. manufacturing capacity. It is not yet clear whether these tariffs would apply to the importation of active pharmaceutical ingredients and possibly bulk drug products that are intended for use in clinical trials”
SEC filing →As of 2026
Supplier concentration
- third-party CMO manufacturing (no owned facilities)medium
Jade owns no manufacturing facilities — all preclinical/clinical drug supply development, manufacturing, storage, distribution and testing is outsourced to third-party CMOs — so it depends on those manufacturers' performance and capacity.
“All of our preclinical and clinical drug supply development, manufacturing, storage, distribution and testing are outsourced to third-party manufacturers and facilities.”
SEC filing →As of 2026
The hidden graph
Who it depends on, and who depends on it.
Relationships surfaced from filings, including ones disclosed by the other side, which is how the non-obvious ones come to light.
Its suppliers
Paragon Therapeutics
“We rely on our collaboration with a third party, Paragon, for a substantial portion of our discovery capabilities and for the rights necessary to develop and commercialize our product candidates.”
Cited →
In the MyPRIA app, this is checked against the companies you actually own.
← World Watch